为何我们独自开展?实验室自建检测开发与验证的协作框架
本文针对美国实验室自建检测(LDT)监管与报销框架制约创新和延迟必需诊断测试实施的问题,提出一个聚焦感染性疾病分子诊断的务实协作模型。该模型保持分析严谨性,允许临床有效性由医学文献证据和临床判断支持,并设想建立自愿性国家数据库,由实验室和制造商贡献标准化分析与临床验证数据。通过共享高质量证据,医院实验室可减少重复验证、加快LDT本地实施,制造商也可用于扩展已获FDA批准检测的预期用途。
要点
- LDT对罕见感染及高危或免疫受损患者群体的未满足诊断需求至关重要。
- 现行美国监管与报销框架制约创新并延迟许多必需实验室诊断测试的实施。
- 提出的协作模型通过共享标准化验证数据减少重复验证,加速检测可及。
核心结论
- 协作框架可增强医院实验室诊断能力、加速检测实施并改善患者结局和医疗系统效率。
研究设计与样本
- 本文为观点/框架提案,未报告系统检索或样本量,提出聚焦感染性疾病分子诊断的务实协作模型。
主要发现
- 现行美国监管与报销框架制约创新并延迟许多必需实验室诊断测试的实施。
- 自愿性国家数据库可汇集实验室和制造商针对新开发及修改的FDA清除检测的标准化分析与临床验证数据。
- 数据元素包括准确度、检测限、分析测量范围、分析特异性和包容性,并与参考测定比较,按技术相同检测分组汇总。
关键数值与推荐
- 数据元素包括准确度、检测限、分析测量范围、分析特异性和包容性,并与参考测定比较。
- 数据在代表技术相同检测的组内汇总,支持累积验证和高质量证据共享。
临床怎么用
- 医院实验室可利用共享数据集以最少重复验证在本地实施LDT,实现更广泛的患者附近检测和更快周转时间。
- 制造商可利用相同数据支持扩展现有FDA清除和批准检测的预期用途申请。
局限性
- 本文为框架提案,未报告实证数据、样本量或验证研究结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Laboratory-developed tests (LDTs) play a critical role in meeting unmet diagnostic needs, particularly for rare infections and high-acuity or immunocompromised patient populations. However, current US regulatory and reimbursement frameworks have constrained innovation and delayed implementation of many essential laboratory diagnostic tests. Here, we propose a pragmatic, collaborative model focusing on infectious disease molecular diagnostics that maintains analytical rigor while allowing clinical validity to be supported by evidence from the medical literature and clinical judgment. To address the resource constraints faced by hospital laboratories, we envision a voluntary, national repository where laboratories and manufacturers contribute standardized analytical and, where appropriate, clinical validation data for both newly developed and modified Food and Drug Administration (FDA)-cleared assays. Data elements such as accuracy, limit of detection, analytical measurement range, analytical specificity, and inclusivity compared with reference determinations would be aggregated within groups representing technically identical assays, enabling cumulative validation and shared use of high-quality evidence. By leveraging these shared data sets, hospital laboratories could implement LDTs in-house with minimal redundant validation, enabling broader access to testing near the point of patient care and faster turnaround times. Manufacturers could use the same data to support applications for expanded intended use of existing FDA-cleared and -approved tests. This framework would strengthen hospital laboratory diagnostic capacity, accelerate test implementation, and improve patient outcomes and healthcare system efficiency.
引用
- Kirby JE, Arnaout R. Why are we doing this alone? A collaborative framework for LDT development and validation. J Clin Microbiol. 2026. PMID: 41854436. doi:10.1128/jcm.01867-25
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。